Your search for major depressive disorder returned 118 results

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Is there a causal relationship between depressive disorders and late-life neurodegenerative diseases? Or, is their co-occurrence due to confounding or common risk factors, such as aging?

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

In early Parkinson Disease, fatigue, excessive daytime sleepiness, and emotional apathy are predictive of increasing fatigue severity.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

There is no evidence supporting the causal role of disturbed sleep patterns on AD or between major depression and AD.

Higher levels of outdoor artificial light at night are associated with less favorable sleep patterns as well as mood and anxiety disorders in adolescents.

Study findings do not support the use of vitamin D3 supplementation to prevent depression in adults.

The use of genetic evaluation for suicidal ideation may represent a future application for precision medicine.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

The applications are supported by positive results from a double-masked, 4-week, pivotal phase 2/3 clinical trial that compared the effects of tasimelteon to placebo in 25 patients with SMS.

Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.

Children who receive a depression diagnosis in their primary school age have a substantially higher risk of a depression relapse during adolescence compared with children who did not receive a depression diagnosis during their primary school age.

Heightened cognitive arousal at bedtime is linked to objective sleep disturbances and indicators of psychological hyperarousal at night and during the day.

Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.

While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.

While insomnia medication efficacy has been studied in meta-analyses, this efficacy has largely been focused on study endpoints rather than time-course responses.

The researchers concluded that the correlation between interregional cortical thinning during maturation and expression patterns of genes associated with multiple psychiatric disorders suggested a common molecular process.

The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease agitation.

Investigators posit that wearable devices will help psychiatrists to target mood and cognitive interventions.

Digital CBT involved 6 weekly remote sessions via website or iOS app lasting approximately 20 minutes and comprised sleep restriction, stimulus control, relaxation techniques, cognitive therapy, and sleep hygiene and education.

Children with PANS have cerebral microstructural differences in multiple brain structures, including the deep gray matter structures.

The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.

The study compared improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging in patients with TRD receiving rTMS treatment.

The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.

Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

Depression contributed to elevated ratings in patients with MDD on items related to perceived inability to cope with the negative consequences of disturbed sleep and reported tendency to cancel social plans after poor sleep.

Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.

Overall, in all patients with MDD, sleep ultradian cycle number was positively associated with REMS percentage, REMS duration, and REMS/NREMS ratio and negatively associated with REM latency.